Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases.
Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would boost earnings and strengthen its presence in treatments for rare diseases.
Wall Street futures, dollar dip after U.S. government shutdown, Asia resilient
TOKYO (Reuters) – Wall Street stock futures and the dollar pulled back slightly on Monday after the U.S. government was forced to shut down amid a dispute between President Donald Trump and Democrats over immigration.
Exclusive: U.S. sanctions curb Microsoft sales to hundreds of Russian firms
MOSCOW (Reuters) – Two of Microsoft’s official distributors in Russia have imposed restrictions on sales of Microsoft software to more than 200 Russian companies following new U.S. sanctions, according to notifications circulated by the distributors.
Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion
PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatments for rare diseases.
Icahn, Deason to jointly push Xerox to explore selling itself, other options: WSJ
(Reuters) – Investor Carl Icahn and Darwin Deason, the biggest- and third-largest shareholders of Xerox Corp, jointly plan to push the printer and photocopier maker to explore options, including a sale of the firm, the Wall Street Journal reported on S…
Oil rises as Saudi Arabia says producers will cooperate beyond 2018
LONDON (Reuters) – Crude futures edged higher on Monday, propped up by comments from Saudi Arabia that cooperation between oil producers who have cut production to boost prices would continue beyond 2018.
Sanofi set to buy Bioverativ for more than $11.5 billion: WSJ
(Reuters) – Sanofi SA is close to a deal to take over U.S. drug maker Bioverativ Inc for more than $11.5 billion, the Wall Street Journal reported, citing people familiar with the matter.
Toshiba considering IPO for memory chip unit: FT
TOKYO (Reuters) – Toshiba Corp is considering an IPO of its prized memory chip business if an agreed $18 billion sale to a Bain Capital-led consortium fails to gain antitrust approval by the end of March, the Financial Times reported on Monday.
Oil prices rise on decline in U.S. drilling, Syria conflict
SINGAPORE (Reuters) – Oil prices climbed on Monday, pushed up by a drop in U.S. drilling activity and by fighting in Syria between Turkish forces and Kurdish fighters.
